Last reviewed · How we verify
NCT04865003
Prognostic Factors for Descending Necrotizing Mediastinitis Development in Deep Space Neck Infections
trial testing treatment of infection in Infection in 289 participants. Completed in 31 December 2020.
31 December 2020
Quick facts
| Lead sponsor | Clinical Center of Vojvodina |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 289 |
| Start date | 1 January 2014 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- treatment of infection
Conditions studied
- Infection — all drugs for Infection →
- Mediastinitis — all drugs for Mediastinitis →
- Neck Abscess — all drugs for Neck Abscess →
- Inflammation — all drugs for Inflammation →
Sponsor
Clinical Center of Vojvodina
Who can join
Eligibility, any sex, with Infection or Mediastinitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Descending necrotizing mediastinitis (DNM) is the most serious complication of deep neck infections (DNI) with high mortality. The objective of this retrospective study was to evaluate possible prognostic factors for DNM development in deep space neck infections.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic factors for descending necrotizing mediastinitis development in deep space neck infections-a retrospective study.
Brajkovic D, Zjalić S, Kiralj A. · · 2022 · cited 12× · PMID 34542654 · DOI 10.1007/s00405-021-07081-0
Verify or expand the search:
- PubMed search for NCT04865003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infection
Currently open trials in the same condition.
- NCT07358117 — Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome · active not recruiting
- NCT07110636 — Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients · NA · recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT07370948 — Study of the Antibiotic-resistance Profile of Enterobacterales Isolated From Rectal Mucosal Buffer of PrEP Subjects · recruiting
Other Clinical Center of Vojvodina trials
Trials by the same sponsor.
- NCT07416721 — Cooling of the Knee After Total Knee Arthroplasty · NA · not yet recruiting
- NCT07405840 — Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage · Phase 4 · active not recruiting
- NCT06030791 — BTB Graft Harvest and Donor Site Morbidity After ACL Reconstruction · unknown
- NCT06838585 — Intra-Abdominal Sepsis and Relationship Between Cumulative Fluid Balance and Serum Sodium and Chloride Levels and In-Hos · completed
- NCT05390294 — Survival With Patients Treated With Salivary Gland Cancer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04865003 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Center of Vojvodina
- Last refreshed: 29 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04865003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing